Identification
- Generic Name
- Solabegron
- DrugBank Accession Number
- DB06190
- Background
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Solabegron (DB06190)
- Weight
- Average: 410.9
Monoisotopic: 410.1397203 - Chemical Formula
- C23H23ClN2O3
- Synonyms
- Solabegron
- External IDs
- GW 427353
Pharmacology
- Indication
Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UBeta-3 adrenergic receptor agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Solabegron can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Solabegron is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Solabegron is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Solabegron. Aclidinium The risk or severity of Tachycardia can be increased when Solabegron is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Solabegron. Alclofenac The risk or severity of hypertension can be increased when Solabegron is combined with Alclofenac. Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Solabegron. Alfuzosin The therapeutic efficacy of Solabegron can be decreased when used in combination with Alfuzosin. Aliskiren Solabegron may decrease the antihypertensive activities of Aliskiren. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Solabegron hydrochloride GU14FR8D4A 451470-34-1 PMXCGBVBIRYFPR-FTBISJDPSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Biphenyls and derivatives
- Direct Parent
- Biphenyls and derivatives
- Alternative Parents
- Benzoic acids / Phenylalkylamines / Aniline and substituted anilines / Benzoyl derivatives / Secondary alkylarylamines / Chlorobenzenes / Aryl chlorides / Secondary alcohols / 1,2-aminoalcohols / Amino acids show 8 more
- Substituents
- 1,2-aminoalcohol / Alcohol / Amine / Amino acid / Amino acid or derivatives / Aniline or substituted anilines / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride show 24 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 55P6YH9O6N
- CAS number
- 252920-94-8
- InChI Key
- LLDXOPKUNJTIRF-QFIPXVFZSA-N
- InChI
- InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1
- IUPAC Name
- 3'-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]-[1,1'-biphenyl]-3-carboxylic acid
- SMILES
- [H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1
References
- General References
- Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR: Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1114-9. doi: 10.1152/ajpgi.00051.2008. Epub 2008 Mar 27. [Article]
- Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP: GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007 Oct;323(1):202-9. Epub 2007 Jul 12. [Article]
- External Links
- PubChem Compound
- 9887812
- PubChem Substance
- 347827760
- ChemSpider
- 8063484
- BindingDB
- 50002595
- ChEBI
- 141346
- ChEMBL
- CHEMBL208427
- ZINC
- ZINC000001547346
- Wikipedia
- Solabegron
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Diagnostic Irritable Bowel Syndrome (IBS) 1 2 Completed Treatment Overactive Bladder Syndrome (OABS) 3 1 Completed Diagnostic Irritable Bowel Syndrome (IBS) 1 1 Completed Treatment Healthy Subjects, Overactive Bladder 1 1 Completed Treatment Overactive Bladder Syndrome (OABS) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00167 mg/mL ALOGPS logP 3.67 ALOGPS logP 1.61 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 4.01 Chemaxon pKa (Strongest Basic) 9.02 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 81.59 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 116.75 m3·mol-1 Chemaxon Polarizability 45.24 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9399 Blood Brain Barrier + 0.7481 Caco-2 permeable - 0.5411 P-glycoprotein substrate Substrate 0.7467 P-glycoprotein inhibitor I Non-inhibitor 0.8542 P-glycoprotein inhibitor II Non-inhibitor 0.8907 Renal organic cation transporter Non-inhibitor 0.7937 CYP450 2C9 substrate Non-substrate 0.7838 CYP450 2D6 substrate Non-substrate 0.8299 CYP450 3A4 substrate Non-substrate 0.6663 CYP450 1A2 substrate Inhibitor 0.5132 CYP450 2C9 inhibitor Non-inhibitor 0.6705 CYP450 2D6 inhibitor Non-inhibitor 0.6447 CYP450 2C19 inhibitor Non-inhibitor 0.6671 CYP450 3A4 inhibitor Non-inhibitor 0.8394 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7415 Ames test Non AMES toxic 0.5071 Carcinogenicity Non-carcinogens 0.7194 Biodegradation Not ready biodegradable 0.9856 Rat acute toxicity 2.5218 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7658 hERG inhibition (predictor II) Inhibitor 0.5771
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
- Gene Name
- ADRB3
- Uniprot ID
- P13945
- Uniprot Name
- Beta-3 adrenergic receptor
- Molecular Weight
- 43518.615 Da
References
- Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR: Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1114-9. doi: 10.1152/ajpgi.00051.2008. Epub 2008 Mar 27. [Article]
Drug created at March 19, 2008 16:16 / Updated at February 21, 2021 18:52